Top 10 Genetics Startups to Watch in 2026

Executive Summary

LONDON, March 26, 2026 — The genetics startup landscape is undergoing a transformation characterised by groundbreaking technologies. A significant factor propelling this change is the global genomics market, projected to reach $94.86 billion by 2030, according to Grand View Research. With a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030, this sector is ripe for innovation. The US alone is expected to see its genomics market grow to $26.94 billion by 2033, driven by developments in next-generation sequencing (NGS) and personalised medicine. From CRISPR-based diagnostics to AI-accelerated drug discovery, the ten startups profiled below represent the most commercially significant and scientifically credible companies shaping the genetics industry in 2026. ---

Top 10 Genetics and Genomics Startups to Watch in 2026

Startup	Country	Founded	Focus Area	Key Technology
Tune Therapeutics	USA	2021	Epigenetic therapy	CRISPR effectors for gene silencing without DNA cutting
SpliceBio	UK	2020	Gene therapy delivery	Intein-based large gene delivery platform
Kailera Therapeutics	USA	2023	Obesity and metabolic disease	AI-driven drug discovery pipeline
Dyno Therapeutics	USA	2018	Gene therapy delivery	AI-designed AAV capsids for in vivo precision delivery
ReCode Therapeutics	USA	2019	mRNA and gene correction	Specialised lipid nanoparticle delivery systems
Axonis Therapeutics	USA	2020	Neurological disorders (CNS)	Transformative CNS therapeutics with significant Series B funding
Mammoth Biosciences	USA	2017	CRISPR diagnostics	Novel Cas enzymes for ultra-fast, high-accuracy molecular tests
Deep Genomics	Canada	2015	Rare genetic diseases	AI genomics platform predicting and designing genetic therapies
eGenesis	USA	2015	Xenotransplantation	Gene-edited pigs engineered for human-compatible organ transplants
Nextbiotics	USA / Brazil	2019	Antimicrobial resistance	Synthetic biology plus bacteriophage technology targeting AMR bacteria

---

Startup Profiles

1. Tune Therapeutics — Epigenetic Gene Silencing Without Cutting DNA

Tune Therapeutics (USA, founded 2021) represents one of the most conceptually significant departures from classical CRISPR gene editing. Rather than cutting DNA strands — which carries inherent off-target risk — Tune uses CRISPR effectors to perform large-scale epigenetic tuning, selectively silencing diseased genes at the regulatory level. This approach preserves the DNA sequence intact while modifying gene expression, dramatically reducing safety concerns that have historically delayed gene therapy approvals. The company's Tune-C platform is in preclinical development across multiple disease areas including liver disease and haematological conditions.

2. SpliceBio — Breaking the Cargo Limit in Gene Therapy

SpliceBio (UK, founded 2020) addresses one of the most persistent bottlenecks in the gene therapy field: the strict cargo size limits imposed by adeno-associated virus (AAV) vectors. Standard AAV packages can carry only approximately 4.7 kilobases of genetic material — far too small for many therapeutic genes. SpliceBio's proprietary intein-based protein splicing platform enables the delivery of large therapeutic genes by splitting them across two AAV particles, which then reassemble inside the target cell. The company is targeting conditions including Usher syndrome, ABCA4-related retinal dystrophies, and DYSF-related muscular dystrophies.

3. Kailera Therapeutics — AI Drug Discovery Targeting the Metabolic Disease Epidemic

Kailera Therapeutics (USA, founded 2023) represents the convergence of AI-driven molecular discovery with the most commercially significant disease area of the 2020s: obesity and metabolic disease. The company has emerged from stealth with a pipeline focused on next-generation GLP-1 receptor agonists and related metabolic targets, using machine learning to identify and optimise novel molecular structures beyond the incremental modifications that characterise most clinical-stage competitors. With GLP-1 drugs projected to generate over $100 billion in annual revenues by 2030, Kailera's AI-first approach to the space has attracted significant investor attention.

4. Dyno Therapeutics — AI-Engineered AAV Capsids for Precision Delivery

Dyno Therapeutics (USA) uses machine learning to engineer novel AAV capsid variants with dramatically improved tissue targeting, immune evasion, and manufacturing characteristics. AAV capsid design has historically been constrained by the natural diversity of serotypes discoverable from nature — Dyno's CapsidMap platform generates and screens millions of synthetic capsid sequences computationally, accelerating the development of gene therapy vectors optimised for specific tissues including liver, CNS, and muscle. Dyno's approach addresses a central bottleneck in precision medicine: getting the right gene to the right cell efficiently and safely at therapeutic scale.

5. ReCode Therapeutics — Lipid Nanoparticle Delivery Beyond the Liver

ReCode Therapeutics (USA) specialises in mRNA delivery and gene correction using selective organ-targeting lipid nanoparticles (SORT LNPs). While most lipid nanoparticle platforms — including those behind the COVID-19 mRNA vaccines — predominantly deliver to the liver, ReCode's technology can be tuned to preferentially deliver to the lungs and other organ systems, expanding the addressable disease space for mRNA therapeutics significantly. The company is advancing treatments for cystic fibrosis and primary ciliary dyskinesia, conditions where pulmonary delivery is essential.

6. Axonis Therapeutics — Targeting the CNS with Gene Therapy

Axonis Therapeutics (USA, Cambridge) focuses exclusively on neurological disorders, a disease area where gene therapy has historically faced the additional challenge of crossing the blood-brain barrier. With significant Series B funding and a pipeline targeting conditions including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy subtypes, Axonis is advancing intrathecal and intravenous delivery strategies designed for CNS penetration. The company's scientific advisory board includes leading neuroscientists from Harvard and MIT, reflecting the academic depth of its approach.

7. Mammoth Biosciences — Novel CRISPR Enzymes for Diagnostics

Mammoth Biosciences (USA, founded 2017) has built a platform based on novel CRISPR-associated (Cas) enzymes discovered through systematic characterisation of microbial diversity. The company's Cas14 and CasΦ enzymes are significantly smaller than the Cas9 commonly associated with CRISPR, enabling ultra-fast, ultra-sensitive molecular diagnostic applications including point-of-care disease detection. Mammoth's DETECTR platform demonstrated sub-hour SARS-CoV-2 detection during the pandemic and is now being applied across infectious disease, oncology biomarker detection, and agricultural applications. Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth holds a significant IP position in the next-generation CRISPR enzyme landscape.

8. Deep Genomics — AI for Rare Genetic Disease Drug Discovery

Deep Genomics (Canada, founded 2015) applies large-scale machine learning to predict how genetic variants affect biological systems and to design genetic medicines targeting rare conditions. The company's AI Workbench integrates genomic, transcriptomic, and proteomic data to identify therapeutic targets that are invisible to conventional experimental approaches. Deep Genomics is advancing antisense oligonucleotide (ASO) programmes for rare neuromuscular conditions including Wilson disease and spinal muscular atrophy, with its AI-first methodology significantly compressing the discovery timeline from years to months.

9. eGenesis — Gene-Edited Xenotransplantation

eGenesis (USA, founded 2015) is advancing one of the most audacious programmes in the genetics field: engineering pigs with dozens of simultaneous genomic modifications to make their organs compatible with the human immune system. The company's 2023 pig-to-human kidney transplant, performed at Massachusetts General Hospital, demonstrated that gene-edited xenotransplantation is no longer a theoretical possibility. With over 100,000 people currently on transplant waiting lists in the US alone, successful xenotransplantation represents one of the highest-impact potential applications of genetic engineering in clinical medicine.

10. Nextbiotics — Synthetic Biology Against Antibiotic Resistance

Nextbiotics (USA/Brazil) merges synthetic biology with bacteriophage technology to create precision antimicrobial therapies targeting antibiotic-resistant bacteria — one of the World Health Organization's declared global health emergencies. Unlike broad-spectrum antibiotics that disrupt the entire microbiome, phage-based therapies can be engineered to target specific pathogenic strains with high precision. Nextbiotics is engineering synthetic phage constructs with enhanced bacterial killing efficiency and resistance-evasion properties, with programmes targeting carbapenem-resistant Enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA). ---

Key Trends Shaping Genetics and Genomics in 2026

AI-Driven Drug Discovery

Artificial intelligence is compressing the drug discovery timeline across the genetics sector. Platforms from Insilico Medicine and Recursion Pharmaceuticals are being heavily used to identify novel drug targets, predict molecular behaviour, and optimise clinical candidates at a fraction of the time and cost of traditional approaches. The integration of multi-omics data — genomics, proteomics, metabolomics — with large language models trained on biological data is enabling target identification for diseases previously considered undruggable.

In Vivo Gene Editing at Scale

The industry is accelerating a fundamental shift from ex vivo gene editing — removing cells, editing them in a laboratory, and reinfusing them — to direct in vivo delivery, where editing tools are administered systemically and act inside the patient's body. Intellia Therapeutics is advancing systemic in vivo CRISPR treatments for transthyretin amyloidosis and haemophilia, demonstrating durable efficacy from a single administration. This approach dramatically broadens the patient population that can benefit from gene therapy beyond those who can tolerate intensive ex vivo procedures.

Molecular Diagnostics and Non-Surgical Detection

Companies such as Hera Biotech are developing non-surgical methods for early disease detection — including menstrual fluid-based diagnostics for endometriosis — exploiting genetic biomarker analysis to bring historically underserved conditions into the clinical mainstream. The convergence of liquid biopsy technology, CRISPR-based detection (Mammoth, Sherlock Biosciences), and AI-powered biomarker interpretation is creating a new generation of diagnostics that are faster, less invasive, and more accessible than tissue biopsy.

Next-Generation Sequencing Expanding the Frontier

Oxford Nanopore Technologies remains a key platform player, with its long-read sequencing technology driving advances in diagnostics, pharmacogenomics, and agricultural genomics. Long-read sequencing resolves structural variants and repetitive genomic regions that short-read platforms miss — critical for identifying the genetic architecture of complex diseases, tracking pathogen evolution, and enabling population-scale genomic screening programmes. The falling cost of sequencing, now approaching $100 per human genome, is making genetic medicine economically viable at population scale for the first time. ---

Genetics Market Statistics — 2024 to 2026 Forecasts

Category	Metric	Year	Value	Source
Global Genomics Market	Market Size	2024	$77.9 billion	Grand View Research
U.S. Genomics Market	Market Size	2025	$22.32 billion	Grand View Research
Global Genomics Market	Projected Size	2026	$84.7 billion	Fortune Business Insights
Global Genomics Market	Projected Size	2030	$94.86 billion	Grand View Research
Next-Gen Sequencing	Lab Adoption Rate	2025	75% of genomic labs	Grand View Research
CRISPR Technologies	Usage Growth	2026	33% YoY increase	Grand View Research
GLP-1 Drug Market	Projected Revenue	2030	$100+ billion	Industry consensus

---

What Comes Next — 12 to 36 Month Outlook

The genetics startup sector is entering a period of clinical validation that will separate companies with durable platforms from those with single-programme pipelines. The next 24 months will be decisive across three fronts: first-in-human trials for in vivo CRISPR editing beyond transthyretin amyloidosis; the commercial scale-up of AI-designed gene therapy vectors; and the first regulatory approvals for xenotransplantation-derived organs in the United States and Europe. Consolidation is also likely. Large pharmaceutical companies — Pfizer, Novartis, Sanofi — are maintaining active business development pipelines in gene therapy delivery, rare disease genetics, and AI-driven genomics. The valuations of several startups on this list reflect the strategic premium attached to proprietary platform technologies rather than individual clinical assets. Investors and enterprise buyers should focus on platform defensibility, manufacturing scalability, and regulatory pathway clarity when evaluating genetics sector positioning through 2028. ---

References

• Grand View Research — Global Genomics Market Analysis
• Fortune Business Insights — Genomics Market Report
• Tune Therapeutics — Official Website
• SpliceBio — Official Website
• Kailera Therapeutics — Official Website
• Dyno Therapeutics — Official Website
• ReCode Therapeutics — Official Website
• Axonis Therapeutics — Official Website
• Mammoth Biosciences — Official Website
• Deep Genomics — Official Website
• eGenesis — Official Website
• Nextbiotics — Official Website
• Intellia Therapeutics — In Vivo Gene Editing Platform
• Oxford Nanopore Technologies
• Grand View Research — U.S. Genomics Market Outlook